Free shipping on orders from 160 €from 160 € 3-vial Retatrutide 30 mg pack at 150 € See the packs
ORDER

Buy Tirzepatide 10mg | GLP-1/GIP Dual Agonist Peptide

Rated 5.00 out of 5 based on 1 customer rating
(1 (Customer review)

49,90 €

Tirzepatide 10 mg (LY3298176): dual GIP and GLP-1 receptor agonist, often shortened to “tirze”. Lyophilized powder, store at -20 °C. Shipping within Europe in 2 to 5 business days.

Shipping within the EU: €10 flat rate · Delivery in 2–5 business days · Ships from the EU

Category :

Tirzepatide (research code LY3298176) is a 39-amino-acid peptide developed by Eli Lilly. It activates two incretin receptors, the GIP receptor and the GLP-1 receptor, hence its nickname: dual agonist. This vial contains 10 mg of lyophilized tirzepatide.

At a glance

  • Product: 1 vial of 10 mg tirzepatide, lyophilized powder.
  • Vial price: €49.90 per vial, or €4.99 per mg.
  • Molecule: dual GIP and GLP-1 receptor agonist, modified with a fatty acid.
  • Analysis: no Janoshik report published yet for this product.
  • Shipping: 2 to 5 business days from the European Union, €10 delivery, free from €160.
  • Intended use: scientific laboratory research only.

Tirzepatide, Mounjaro and Zepbound

The same molecule is marketed as a medicine by Eli Lilly under the names Mounjaro and Zepbound, in ready-to-use pens and on prescription. The vial sold here is not that medicine: it is a lyophilized research peptide, for laboratory use only.

Mechanism of action

Tirzepatide mimics two gut hormones, GIP and GLP-1. Through the GLP-1 receptor, it reduces appetite, slows gastric emptying and stimulates insulin secretion when blood glucose rises. Through the GIP receptor, it enhances insulin secretion and helps regulate lipid metabolism.

Its action is not symmetrical. An Eli Lilly study shows that at the concentrations reached clinically, it occupies the GIP receptor more than the GLP-1 receptor. At the GLP-1 receptor, it favors cAMP production over β-arrestin recruitment, which limits receptor internalization (Willard, 2020).

A fatty acid chain allows it to bind to albumin in the blood, which extends its duration of action (Coskun, 2018).

What the clinical trials show

  • SURMOUNT-1, obesity: 2,539 adults followed for 72 weeks. Mean weight loss of 15.0 to 20.9% depending on the group, versus 3.1% with placebo (Jastreboff, 2022).
  • SURPASS-2, type 2 diabetes: 1,879 patients followed for 40 weeks. Greater HbA1c reduction than with semaglutide, 2.01 to 2.30 points versus 1.86, and greater weight loss (Frías, 2021).
  • SURMOUNT-4, weight maintenance: after 36 weeks of treatment and an average weight loss of 20.9%, participants switched to placebo regained 14.0% of their weight over 52 weeks. Those who continued tirzepatide lost a further 5.5% (Aronne, 2024).
  • Adverse effects: mainly gastrointestinal, mostly mild to moderate (Jastreboff, 2022).

These results concern the medicine, in supervised trials. They do not describe a research peptide.

Tirzepatide, semaglutide or Retatrutide?

Molecule Receptors Status Published weight loss
Semaglutide GLP-1 Approved as a medicine (Ozempic, Wegovy) 14.9% in 68 weeks (STEP 1)
Tirzepatide GIP and GLP-1 Approved as a medicine (Mounjaro, Zepbound) Up to 20.9% in 72 weeks (SURMOUNT-1)
Retatrutide GIP, GLP-1 and glucagon In phase 3, not approved Up to 24.2% in 48 weeks (phase 2)

These figures come from different trials, run in different populations and over different durations: the comparison remains indirect.

Technical specifications

Molecule Tirzepatide, LY3298176
Type 39-amino-acid peptide, modified with a fatty acid
Molecular formula C₂₂₅H₃₄₈N₄₈O₆₈
Molecular weight 4,813.53 g/mol
Quantity per vial 10 mg
Form Lyophilized powder
Analysis No Janoshik report published yet
Storage -20 °C before reconstitution

Reconstitution and storage

Tirzepatide is reconstituted with bacteriostatic water (0.9% benzyl alcohol). Let the water run down the inside wall of the vial, then swirl gently, without shaking. The volume of water sets the concentration: with 1 mL, the solution contains 10 mg per mL.

Before reconstitution, store the vial at -20 °C. After reconstitution, keep the solution between 2 and 8 °C and use it within 4 weeks. Avoid repeated freezing and thawing.

Tirzepatide price

The 10 mg vial costs €49.90, or €4.99 per mg. Delivery €10, free from €160.

Shipping

Discreet packaging and shipping in 2 to 5 business days to the EU countries we serve. Overseas territories and Norway: longer lead time.

Secure payment by credit card, Apple Pay or Google Pay.

MyPeptide is a European shop based in Paris. This product is intended exclusively for scientific research.

Frequently asked questions about tirzepatide 10 mg

What is tirzepatide?

Tirzepatide (LY3298176) is a 39-amino-acid peptide that activates the receptors of both GIP and GLP-1, two gut hormones that regulate blood glucose and appetite. It was developed by Eli Lilly.

Is tirzepatide the same product as Mounjaro?

It is the same molecule, but not the same product. Mounjaro and Zepbound are Eli Lilly medicines, dispensed on prescription in ready-to-use pens. Our vial is a lyophilized research peptide, for laboratory use only.

What is the difference between tirzepatide and semaglutide?

Semaglutide activates only the GLP-1 receptor; tirzepatide also activates the GIP receptor. In the SURPASS-2 trial, which compared them head to head in patients with diabetes, tirzepatide lowered HbA1c and weight more.

What is the difference between tirzepatide and Retatrutide?

Retatrutide activates a third receptor, the glucagon receptor. It is still in phase 3 and is not approved as a medicine. Its phase 2 trial reports up to 24.2% weight loss in 48 weeks, versus up to 20.9% in 72 weeks for tirzepatide in SURMOUNT-1, but these are different trials.

Why is tirzepatide called an imbalanced agonist?

At the concentrations reached clinically, tirzepatide occupies the GIP receptor more than the GLP-1 receptor. At the GLP-1 receptor, it mainly activates the cAMP pathway, with little β-arrestin recruitment. This signature was described by Willard and colleagues in 2020.

What does the vial contain?

10 mg of lyophilized tirzepatide, in powder form. The vial contains no solvent: bacteriostatic water is sold separately or in the Reconstitution Pack.

How should tirzepatide be reconstituted and stored?

With bacteriostatic water, added slowly down the inside wall, without shaking. Before reconstitution, store the vial at -20 °C; afterwards, keep the solution between 2 and 8 °C and use it within 4 weeks.

Do you have an analysis report for tirzepatide?

Not yet. We have not published a Janoshik report for this product. Our published reports, with their number and verification key, are on the certificates of analysis page.

How much does tirzepatide 10 mg cost?

€49.90 for the 10 mg vial, or €4.99 per mg. Delivery costs €10 and is free from €160.

How long does delivery take?

We ship in 2 to 5 business days to the EU countries we serve. Delivery costs €10 and is free from €160.

Sources

  1. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Molecular Metabolism, 2018.
  2. Willard FS et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 2020.
  3. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). New England Journal of Medicine, 2021.
  4. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022.
  5. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA, 2024.
  6. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021.
  7. Jastreboff AM et al. Triple-hormone-receptor agonist retatrutide for obesity, a phase 2 trial. New England Journal of Medicine, 2023.
Weight 0.5 kg

1 review for Buy Tirzepatide 10mg | GLP-1/GIP Dual Agonist Peptide

  1. Rated 5 out of 5

    Anonyme –

    I received it.

Add a Review

Your email address will not be published. Required fields are indicated with an asterisk (*). *

FRENDEITESPTNLPLSV
Back to top